Clinical Trial Update: Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

This Phase 3 trial assessed two fixed-dose combinations of aclidinium bromide/formoterol fumarate for 28 weeks in adults with moderate-to-severe COPD, with arms…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide (Aclidinium bromide)
• Aclidinium bromide/Formoterol fumarate (Fixed-dose Combination 1) (aclidinium bromide/formoterol fumarate)
• Aclidinium bromide/Formoterol fumarate (Fixed-dose Combination 2) (aclidinium bromide/formoterol fumarate)
• FORMOTEROL FUMARATE (Formoterol fumarate dihydrate)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-04-21